Exploring the Disconnect Between Lipoprotein(a) Reduction and Cardiovascular Outcomes in the Lp(a)HORIZON Trial

Background

Lipoprotein(a) or Lp(a) is a genetically determined risk factor for atherosclerotic cardiovascular disease; it has the structure of a low density protein with an apolipoprotein(a) covalently bound to apolipoprotein B-100. The Lp(a) HORIZON is an ongoing trial that is testing if lowering the Lp(a) with the antisense oligonucleotide, Pelacarsen, would translate into fewer cardiovascular events.

Methods

A literary review was conducted, we first reviewed the Design and Rationale of Lp(a)HORIZON trial. Subsequently we analyzed the topline results that were published in September 2026 through Ionis and Novartis. Afterwards, we investigated the Lp(a) evidence base that included an overview of the protein with its clinical implications, Mendelian randomization studies, completed PCSK9 inhibitor and niacin trials and other ongoing and concluded RNA based Lp(a) lowering trials.

Results

Lp(a) HORIZON enrolled 8,323 patients with established ASCVD and Lp(a) >70mg/dL (median 108.3mg/dL) randomized to monthly pelecarsen 80mg or placebo. Per September 2026, the trial lowered Lp(a) but did not meet their primary endpoint; a four-component composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and urgent hospitalized coronary revascularization. Acknowledging that Lp(a) lowering did not translate into a demonstrated reduction in cardiovascular risk. Seven distinct non mutually exclusive mechanisms warrant review: delayed therapeutic initiation, limited duration of exposure, failure to attain the absolute Lp(a) reduction of approximately 100 mg/dL implied by Mendelian randomization, the divergence between life-long genetic elevation and transient therapeutic lowering, unaddressed baseline cardiovascular risk, attenuation of effect within a broad composite outcome, and potential heterogeneity across patient subgroups.

Discussion and Conclusion

Lp(a) is an independent, easily measured, and underused risk factor for premature CAD. The Lp(a)HORIZON trial illustrates the gap between successfully modifying a validated risk biomarker and demonstrating patient-important clinical benefit; it does not, by itself, refute the causal role of Lp(a) in atherosclerotic disease. Definitive interpretation requires the full dataset and corroboration from the ongoing Lp(a) HORIZON (Novaris) and lepodisiran (ACCLAIM-Lp(a)) outcomes trials.